FDA Guidance on Enforcement of Regulations Restricting Sale and Distribution of Cigarettes & Smokeless Tobacco

This post was written by Paul Sheives.

FDA has issued a guidance document entitled Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco.” The purpose of the guidance document is to announce the agency’s views on the enforcement of two provisions in its final regulations restricting the sale and distribution of cigarettes and smokeless tobacco to protect children and adolescents. The first provision prohibits the use of trade names for tobacco products on non-tobacco products. FDA is exercising enforcement discretion to stay enforcement of this provision where (1) the trade name of the tobacco product was registered, or the product was marketed, in the U.S. on or before June 22, 2009; or (2) the initial marketing or registration of the tobacco product occurred prior to the same for the non-tobacco product not marketed or registered by the same company or an affiliate. The second provision requires that labeling or print advertisements appear in a black-and white text only format, except in certain “adult only” locations or in publications that do not have significant readership by children and adolescents under the age of 18. Although the guidance document is in effect, FDA is accepting written comments at any time.  

FDA Issues Final Regulations Restricting the Sale and Distribution of Cigarettes

FDA has issued a final rule restricting the sale and distribution of cigarettes. The final rule is very similar to the final rule on cigarettes and smokeless tobacco FDA issued in 1996. The rule prohibits the sale of cigarettes to persons under 18 years of age; distribution of free samples of cigarettes, and distribution of free samples of smokeless tobacco, with certain exceptions. In addition, the rule prohibits the sale of cigarettes and smokeless tobacco products through vending machines and self-service displays, except in facilities void of persons 18 years of age; limits the format for advertising and labeling to which children and adolescents are exposed to black-and-white and text-only; prohibits the sale or distribution of brand-identified promotional nontobacco items such as hats and tee shirts; and prohibits sponsorship of sporting and other events, teams, and entries in a brand name of a tobacco product.

FDA Guidance Documents

This post was written by Paul Sheives.

FDA recently released two guidance documents (one in draft form) concerning hematopoietic reconstitution for specified indications as hematopoietic progenitor cells, cord (HPC-C), which provide information to manufacturers seeking licensure and potential sponsors for Investigational New Drugs Applications (INDs). FDA announced that it no longer intends to exercise enforcement discretion regarding IND and Biologics License Application (BLA) requirements for these products. The final guidance document is entitled “Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications,” and the draft guidance is entitled “Investigational New Drug Applications (INDs) for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications.” Other recent FDA guidance documents include the following: